1. Identification

Product identifier TELAZOL

Other means of identification

Synonyms TELAZOL® * Tiletamine HCL and Zolazepam HCL

Recommended use Veterinary anesthetic agent

Recommended restrictions Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (USA) Zoetis Inc.
10 Sylvan Way
Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison and Drug Center 1-866-531-8896

Product Support/Technical Services 1-800-366-5288

Emergency telephone numbers CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Company Name (CA) Zoetis Canada Inc.
16740 Trans-Canada Highway
Kirkland, Quebec, H9H 4M7

Emergency telephone number International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail productsupport@zoetis.com

Product Support 1-800-461-0917

All Safety Data Sheets are available via our Zoetis Canada website at https://www.zoetis.ca/sds/sds.aspx

Supplier Not available.

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Reproductive toxicity (the unborn child) Category 2
Specific target organ toxicity following single exposure Category 3 narcotic effects
Specific target organ toxicity following repeated exposure Category 2 (central nervous system, kidney, pancreas)

Environmental hazards Not classified.

Label elements

Signal word Warning

Hazard statement May cause drowsiness or dizziness. Suspected of damaging the unborn child. May cause damage to organs (central nervous system, kidney, pancreas) through prolonged or repeated exposure.

Precautionary statement Prevention Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe mist or vapour. Use only outdoors or in a well-ventilated area. Wear protective gloves/protective clothing/eye protection/face protection.
3. Composition/information on ingredients

**Mixtures**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common name and synonyms</th>
<th>CAS number</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannitol</td>
<td></td>
<td>69-65-8</td>
<td>&lt;6</td>
</tr>
<tr>
<td>Tiletamine hydrochloride</td>
<td></td>
<td>14176-50-2</td>
<td>50 mg/ml</td>
</tr>
<tr>
<td>Water for Injection</td>
<td></td>
<td>7732-18-5</td>
<td></td>
</tr>
<tr>
<td>Zolazepam hydrochloride</td>
<td></td>
<td>33754-49-3</td>
<td>50 mg/ml</td>
</tr>
</tbody>
</table>

All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

4. First-aid measures

**Inhalation**

Remove victim to fresh air and keep at rest in a position comfortable for breathing. If breathing is difficult, trained personnel should give oxygen. Get medical attention immediately.

**Skin contact**

Wash off with soap and plenty of water. Remove contaminated clothing. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse.

**Eye contact**

Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses. Continue rinsing. Call a physician or poison control centre immediately.

**Ingestion**

May cause drowsiness and dizziness. Narcosis. Headache. Nausea, vomiting. Behavioural changes. Decrease in motor functions. Prolonged exposure may cause chronic effects. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused respiratory depression, gastrointestinal disturbances, allergic skin rash. Anesthetic drug: may cause central nervous system and cardiovascular system effects. Most important symptoms/effects, acute and delayed

Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed. Anesthetic drug: may cause central nervous system and cardiovascular system effects. Monitor respiratory, cardiac and central nervous system.

**Indication of immediate medical attention and special treatment needed**

IF exposed or concerned: Get medical advice/attention. For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance.

5. Fire-fighting measures

**Suitable extinguishing media**

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

**Unsuitable extinguishing media**

Do not use water jet as an extinguisher, as this will spread the fire.

**Specific hazards arising from the chemical**

During fire, gases hazardous to health may be formed.

**Special protective equipment and precautions for firefighters**

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

**Fire fighting equipment/instructions**

Move containers from fire area if you can do so without risk.

**Specific methods**

Use standard firefighting procedures and consider the hazards of other involved materials.

**General fire hazards**

No unusual fire or explosion hazards noted.

6. Accidental release measures

**Personal precautions, protective equipment and emergency procedures**

Keep unnecessary personnel away. Ensure adequate ventilation. Do not breathe mist or vapour. Avoid contact with eyes, skin, and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8 of the SDS. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up

Ensure adequate ventilation. Avoid release to the environment. Prevent entry into waterways, sewer, basements or confined areas. Remove sources of ignition.

Large Spills: Stop the flow of material, if this is without risk. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Wear appropriate personal protective equipment. Provide adequate ventilation. Avoid breathing mist or vapour. Avoid contact with eyes, skin, and clothing. Avoid accidental injection. Avoid prolonged exposure. Wash thoroughly after handling. When using, do not eat, drink or smoke. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store locked up. Store in a well-ventilated place. @ 15-30°C (59-86°F). Protect from sunlight. Use care in handling/storage. Store away from incompatible materials (see Section 10 of the SDS). Keep out of the reach of children.

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

Biological limit values

No biological exposure limits noted for the ingredient(s).

Control banding approach

Tiletamine hydrochloride: Zoetis OEB 2 (control exposure to the range of 100ug/m3 to < 1000ug/m3)

Zolazepam hydrochloride: Zoetis OEB 3 (control exposure to the range of 10ug/m3 to < 100ug/m3)

Appropriate engineering controls

Ensure adequate ventilation, especially in confined areas. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

Eye/face protection

If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection

Wear protective gloves. Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Other

Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

Respiratory protection

No personal respiratory protective equipment normally required. In case of insufficient ventilation, wear suitable respiratory equipment. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range. Respiratory protection should be provided in instances where exposure to dust, mists, aerosols or vapors are likely. Chemical respirator with organic vapour cartridge, full facepiece, dust and mist filter.

Thermal hazards

Not applicable.

General hygiene considerations

Observe any medical surveillance requirements. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Liquid. (After reconstitution).

Physical state

Liquid.

Form

Liquid.

Colour

Off-white.

Odour

Not available.

Odour threshold

Not available.

pH

3.5

Melting point/freezing point

Not available.
Initial boiling point and boiling range: 100 °C (212 °F)

Flash point: Not available.

Evaporation rate: Not available.

Flammability (solid, gas): Not applicable.

Upper/lower flammability or explosive limits:
- Flammability limit - lower (%): Not available.
- Flammability limit - upper (%): Not available.
- Explosive limit - lower (%): Not available.
- Explosive limit – upper (%): Not available.

Vapour pressure: Not available.

Vapour density: Not available.

Relative density: Not available.

Solubility(ies):
- Solubility (water): Slightly soluble
- Partition coefficient (n-octanol/water): Not available.

Auto-ignition temperature: Not available.

Decomposition temperature: Not available.

Viscosity: Not available.

Other information:
- Explosive properties: Not explosive.
- Oxidising properties: Not oxidising.
- Specific gravity: 1.52 (Mannitol)

10. Stability and reactivity

Reactivity: The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability: Material is stable under normal conditions.

Possibility of hazardous reactions: No dangerous reaction known under conditions of normal use.

Conditions to avoid: Contact with incompatible materials.

Incompatible materials: Strong oxidising agents.

Hazardous decomposition products: Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition. May include products of carbon, nitrogen. May include hydrogen chloride.

11. Toxicological information

Information on likely routes of exposure:
- Inhalation: May cause drowsiness and dizziness. Headache. Nausea, vomiting. May cause irritation to the respiratory system.
- Skin contact: Prolonged skin contact may cause temporary irritation.
- Eye contact: Direct contact with eyes may cause temporary irritation.
- Ingestion: May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics: May cause drowsiness and dizziness. Narcosis. Headache. Nausea, vomiting. Behavioural changes. Decrease in motor functions. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused respiratory depression, gastrointestinal disturbances, allergic skin rash. Anesthetic drug: may cause central nervous system and cardiovascular system effects.

Information on toxicological effects:
- Acute toxicity: May be harmful if inhaled. May be harmful if swallowed.
<table>
<thead>
<tr>
<th>Product</th>
<th>Species</th>
<th>Test results</th>
</tr>
</thead>
<tbody>
<tr>
<td>TELAZOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rat</td>
<td>&gt; 5000 mg/kg (ATE)</td>
</tr>
<tr>
<td><strong>Components</strong></td>
<td><strong>Species</strong></td>
<td><strong>Test results</strong></td>
</tr>
<tr>
<td>Mannitol (CAS 69-65-8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Mouse</td>
<td>22 g/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>13500 mg/kg</td>
</tr>
<tr>
<td>Zolazepam (CAS 31352-82-6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rat</td>
<td>398 mg/kg</td>
</tr>
<tr>
<td><strong>Subchronic</strong></td>
<td><strong>LOAEL</strong></td>
<td><strong>Test results</strong></td>
</tr>
<tr>
<td></td>
<td>Dog</td>
<td>10 mg/kg/day, 3 months [Target organ(s): Central Nervous System, Gastrointestinal system]</td>
</tr>
<tr>
<td></td>
<td>Monkey</td>
<td>10 mg/kg/day, 3 months [Target organ(s): Central Nervous System]</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>10 mg/kg/day, 91 days [Target organ(s): Pancreas, Kidney]</td>
</tr>
</tbody>
</table>

**Skin corrosion/irritation**
- Prolonged skin contact may cause temporary irritation.

**Serious eye damage/eye irritation**
- Direct contact with eyes may cause temporary irritation.

**Respiratory or skin sensitisation**
**Respiratory sensitisation**
- Not a respiratory sensitizer.

**Skin sensitisation**
- Due to partial or complete lack of data the classification is not possible. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

**Germ cell mutagenicity**
- No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

**Carcinogenicity**
- This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

**Reproductive toxicity**
- Suspected of damaging the unborn child. This compound can cross the placenta in pregnant women.

**Specific target organ toxicity - single exposure**
- May cause drowsiness and dizziness.

**Specific target organ toxicity - repeated exposure**
- May cause damage to organs (central nervous system, kidney, pancreas) through prolonged or repeated exposure.

**Aspiration hazard**
- Not an aspiration hazard.

**Chronic effects**
- May cause damage to organs through prolonged or repeated exposure.

**Further information**
- Anesthetic drug: may cause central nervous system and cardiovascular system effects. Accidental injection of this product may result in anesthetic and other central nervous system effects. Convulsions, lethargy, respiratory depression, and muscle relaxation may occur. Cardiovascular effects (increase heart rate, changes in blood pressure) may also occur. Pulmonary edema with resultant shortness of breath may be seen as well as nausea and vomiting.

12. **Ecological information**

**Ecotoxicity**
- The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment. Avoid release to the environment.

**Persistence and degradability**
- No data is available on the degradability of this product.

**Bioaccumulative potential**
- No data available.

**Mobility in soil**
- No data available.
Other adverse effects
No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions
Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations
Dispose in accordance with all applicable regulations.

Hazardous waste code
None known.

Waste from residues / unused products
Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging
Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

TDG
Not regulated as dangerous goods.

IATA
Not regulated as dangerous goods.

IMDG
Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not established.

15. Regulatory information

Canadian regulations
This product has been classified in accordance with the hazard criteria of the HPR and the SDS contains all the information required by the HPR.

Controlled Drugs and Substances Act
Not regulated.

Export Control List (CEPA 1999, Schedule 3)
Not listed.

Greenhouse Gases
Not listed.

Precursor Control Regulations
Not regulated.

International regulations

Stockholm Convention
Not applicable.

Rotterdam Convention
Not applicable.

Kyoto protocol
Not applicable.

Montreal Protocol
Not applicable.

Basel Convention
Not applicable.

International Inventories

Country(s) or region
Australia
Canada

Inventory name
Australian Inventory of Chemical Substances (AICS)
Domestic Substances List (DSL)

On inventory (yes/no)*
No
No
<table>
<thead>
<tr>
<th>Country(s) or region</th>
<th>Inventory name</th>
<th>On inventory (yes/no)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>Non-Domestic Substances List (NDSL)</td>
<td>No</td>
</tr>
<tr>
<td>China</td>
<td>Inventory of Existing Chemical Substances in China (IECSC)</td>
<td>No</td>
</tr>
<tr>
<td>Europe</td>
<td>European Inventory of Existing Commercial Chemical Substances (EINECS)</td>
<td>No</td>
</tr>
<tr>
<td>Europe</td>
<td>European List of Notified Chemical Substances (ELINCS)</td>
<td>No</td>
</tr>
<tr>
<td>Japan</td>
<td>Inventory of Existing and New Chemical Substances (ENCS)</td>
<td>No</td>
</tr>
<tr>
<td>Korea</td>
<td>Existing Chemicals List (ECL)</td>
<td>No</td>
</tr>
<tr>
<td>New Zealand</td>
<td>New Zealand Inventory</td>
<td>No</td>
</tr>
<tr>
<td>Philippines</td>
<td>Philippine Inventory of Chemicals and Chemical Substances (PICCS)</td>
<td>No</td>
</tr>
<tr>
<td>United States &amp; Puerto Rico</td>
<td>Toxic Substances Control Act (TSCA) Inventory</td>
<td>No</td>
</tr>
</tbody>
</table>

*A “Yes” indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A “No” indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information

Issue date 28-April-2017
Version No. 01

List of abbreviations
ATE: Acute Toxicity Estimate according to REGULATION (EC) No 1272/2008 (CLP).

Disclaimer
Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently available.

Revision information
Product and Company Identification: Physical States
Composition / Information on Ingredients: Ingredients
Physical & Chemical Properties: Multiple Properties
Toxicological Information: Toxicological Data
GHS: Qualifiers

Material name: TELAZOL
821 Version #: 01 Issue date: 28-April-2017